SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
|
(Date of earliest event reported): | March 5, 2004 |
Introgen Therapeutics, Inc.
| Delaware | 0-21291 | 74-2704230 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) | ||
| 301 Congress Avenue, Suite 1850, Austin, Texas | 78701 | |
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code:
|
(512) 708-9310 | |
| Item 7. Exhibits. | ||||||||
| Item 9. Regulation FD Disclosure. | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| Press Release | ||||||||
Item 7. Exhibits.
| (c) | Exhibits. | |||
| 99.1 | Press Release dated March 5, 2004. | |||
Item 9. Regulation FD Disclosure.
On March 5, 2004, Introgen Therapeutics, Inc. (the “Company”) issued a press release announcing its plans to offer up to 6,325,000 shares of its common stock in an underwritten public offering (including 825,000 shares issuable upon exercise of the underwriters’ over-allotment option, if any) pursuant to its already effective shelf registration statement. The press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to the Company’s Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at the Company’s Internet address is not part of this Current Report on Form 8-K or any other report filed by the Company with the Securities and Exchange Commission.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 5, 2004
|
INTROGEN THERAPEUTICS, INC. | |
| /s/ James W. Albrecht, Jr. |
||
| James W. Albrecht, Jr. | ||
| Chief Financial Officer |
-3-